Gamida Cell Ltd. (GMDA)

$1.74

-0.03 (-1.69%)
Rating:
Recommendation:
-
Symbol GMDA
Price $1.74
Beta 1.820
Volume Avg. 0.74M
Market Cap 104.374M
Shares () -
52 Week Range 1.67-6.36
1y Target Est -
DCF Unlevered GMDA DCF ->
DCF Levered GMDA LDCF ->
ROE -121.27% Strong Sell
ROA -49.10% Strong Sell
Operating Margin -
Debt / Equity 398.47% Strong Buy
P/E -
P/B 4.14 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest GMDA news


Dr. Julian Adams
Healthcare
Biotechnology
NASDAQ Global Market

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.